ZA988124B - Mage-3 peptides presented by HLA class II molecules - Google Patents

Mage-3 peptides presented by HLA class II molecules

Info

Publication number
ZA988124B
ZA988124B ZA988124A ZA988124A ZA988124B ZA 988124 B ZA988124 B ZA 988124B ZA 988124 A ZA988124 A ZA 988124A ZA 988124 A ZA988124 A ZA 988124A ZA 988124 B ZA988124 B ZA 988124B
Authority
ZA
South Africa
Prior art keywords
mage
hla class
molecules
peptides
peptides presented
Prior art date
Application number
ZA988124A
Other languages
English (en)
Inventor
Pascal Chaux
Thierry Boon-Falleur
Rosalie Luiten
Carlo Heirman
Vincent Stroobant
Pierre Van Der Bruggen
Kris Thielemans
Jurgen Corthals
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of ZA988124B publication Critical patent/ZA988124B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA988124A 1997-09-12 1998-09-04 Mage-3 peptides presented by HLA class II molecules ZA988124B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/928,615 US5965535A (en) 1997-09-12 1997-09-12 Mage-3 peptides presented by HLA class II molecules

Publications (1)

Publication Number Publication Date
ZA988124B true ZA988124B (en) 1999-03-05

Family

ID=25456537

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA988124A ZA988124B (en) 1997-09-12 1998-09-04 Mage-3 peptides presented by HLA class II molecules

Country Status (9)

Country Link
US (2) US5965535A (xx)
EP (1) EP1012283B1 (xx)
JP (1) JP4106179B2 (xx)
AT (1) ATE432983T1 (xx)
AU (1) AU757368B2 (xx)
CA (1) CA2303063C (xx)
DE (1) DE69840868D1 (xx)
WO (1) WO1999014326A1 (xx)
ZA (1) ZA988124B (xx)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0668350B2 (en) * 1994-02-16 2008-12-03 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Melanoma associated antigenic polypeptide, epitopes thereof and vaccines against melanoma
US20040156861A1 (en) * 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
DE69942214D1 (de) 1998-02-05 2010-05-12 Glaxosmithkline Biolog Sa Verfahren zur Reinigung oder Herstellung der MAGE Protein
US6800730B1 (en) * 1998-10-02 2004-10-05 Ludwig Institute For Cancer Research Isolated peptides which bind to MHC class II molecules, and uses thereof
US6710172B1 (en) * 1998-10-02 2004-03-23 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
US6407063B1 (en) * 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
IT1309584B1 (it) * 1999-02-26 2002-01-24 San Raffaele Centro Fond Peptidi immunogenici derivati da mage-3 presentati da mhc di classeii e loro uso.
IT1312568B1 (it) * 1999-05-21 2002-04-22 Genera Spa Peptidi immunogenici e loro uso.
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
US7429639B2 (en) * 1999-09-29 2008-09-30 Ludwig Institute For Cancer Research SSX-2 peptides presented by HLA class II molecules
KR20020047249A (ko) * 1999-10-19 2002-06-21 에드워드 에이. 맥더모트, 주니어 Ｍａｇｅ-ａ12 항원성 펩티드 및 그의 용도
US6897288B1 (en) 1999-10-19 2005-05-24 Ludwig Institute For Cancer Research Mage-A12 antigenic peptides and uses thereof
US6605711B1 (en) * 1999-11-15 2003-08-12 Ludwig Institute For Cancer Research NY-ESO-1 peptide derivatives, and uses thereof
EP1235841A4 (en) * 1999-12-10 2006-04-12 Epimmune Inc TRIGGERING MAGE2 / 3 CELLULAR IMMUNE RESPONSES USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
AU5810201A (en) 2000-05-10 2001-11-20 Aventis Pasteur Immunogenic polypeptides encoded by mage minigenes and uses thereof
US7803382B2 (en) 2001-05-04 2010-09-28 Ludwig Institute For Cancer Research Ltd. Method for inducing immune response to NY-CO-58
US6794501B2 (en) 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
US7049413B2 (en) * 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
WO2002094994A2 (en) * 2001-05-18 2002-11-28 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US20060222656A1 (en) * 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
WO2003085087A2 (en) 2002-04-09 2003-10-16 Aventis Pasteur, Limited Modified cea nucleic acid and expression vectors
EP1518120A4 (en) 2002-03-11 2008-08-13 Momenta Pharmaceuticals Inc ANALYSIS OF SULFATE POLYSACCHARIDES
WO2004037284A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
JP2006505280A (ja) * 2002-11-07 2006-02-16 チャン・ルン−ジ 改変樹状細胞
EP1670926B1 (en) * 2003-10-08 2011-04-20 Sanofi Pasteur Limited Modified cea /b7 vector
US20070154889A1 (en) * 2004-06-25 2007-07-05 Veridex, Llc Methods and reagents for the detection of melanoma
US7858743B2 (en) * 2004-09-09 2010-12-28 Ludwig Institute For Cancer Research SSX-4 peptides presented by HLA class II molecules
EP1805214A2 (en) * 2004-10-20 2007-07-11 Friedrich-Alexander-Universität Erlangen-Nürnberg T-cell stimulatory peptides from the melanoma-associated chondroitin sulfate proteoglycan and their use
WO2008053573A1 (fr) 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remède pour néoplasme malin
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
US9045729B2 (en) 2009-12-10 2015-06-02 Ottawa Hospital Research Institute Oncolytic rhabdovirus
CN102791742B (zh) 2010-01-19 2014-12-24 动量制药公司 评价肝素制剂
WO2012115952A1 (en) 2011-02-21 2012-08-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
EP3622965A1 (en) * 2013-02-21 2020-03-18 Turnstone Limited Partnership Vaccine composition
AU2014300503B2 (en) 2013-06-28 2018-11-22 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
WO2015184224A1 (en) * 2014-05-30 2015-12-03 Academia Sinica Aptamer targeting mage-a3 peptide and uses thereof
CA2971677A1 (en) 2014-12-23 2016-06-30 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
US11464853B2 (en) 2016-02-26 2022-10-11 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
US10441509B2 (en) * 2018-03-16 2019-10-15 Berkshire Biomedical, LLC Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019409D0 (en) * 1990-09-05 1990-10-17 Pfizer Ltd Therapeutic agents
US5139325A (en) * 1991-01-25 1992-08-18 Oksman Henry C Wide depth of focus power add to intraocular and contact lenses
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5348578A (en) * 1991-10-23 1994-09-20 Ppg Industries (France) S.A. Products obtained from the reaction of amine-diol and a polyfunctional substance and application of such products to electroapplicable cationic paint compositions
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
ES2225824T3 (es) * 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
US5414610A (en) * 1993-06-21 1995-05-09 Ast Research, Inc. Universal power converter with single, shared power transformation circuit
WO1995003657A1 (fr) * 1993-07-21 1995-02-02 Fujitsu Limited Central mta
US5851523A (en) 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5585461A (en) * 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
DE69533966T2 (de) * 1994-11-11 2005-06-30 Kabushiki Kaisha Tokai Rika Denki Seisakusho Verfahren zum registrieren eines identifikationskodes
DE4441903C1 (de) * 1994-11-24 1996-03-21 Siemens Ag Drucksensor
US6951917B1 (en) 1995-09-26 2005-10-04 The United States Of America As Represented By The Department Of Health And Human Services MHC-class II restricted melanoma antigens and their use in therapeutic methods
AU7440196A (en) * 1995-10-12 1997-04-30 Chiron Corporation Baboon mage-3 homologs, dna encoding the homologs, and a process for their use
EP2724617A1 (en) 2012-10-25 2014-04-30 Commissariat A L'energie Atomique Et Aux Energies Alternatives Compounds for alleviating phosphate starvation symptoms in plants
US9603182B2 (en) 2013-03-14 2017-03-21 Qualcomm Incorporated Establishing reliable always-on packet data network connections

Also Published As

Publication number Publication date
EP1012283B1 (en) 2009-06-03
CA2303063A1 (en) 1999-03-25
AU9306198A (en) 1999-04-05
JP4106179B2 (ja) 2008-06-25
JP2001516579A (ja) 2001-10-02
WO1999014326A1 (en) 1999-03-25
DE69840868D1 (de) 2009-07-16
EP1012283A1 (en) 2000-06-28
US5965535A (en) 1999-10-12
ATE432983T1 (de) 2009-06-15
CA2303063C (en) 2009-11-24
AU757368B2 (en) 2003-02-20
US6369211B1 (en) 2002-04-09

Similar Documents

Publication Publication Date Title
ZA988124B (en) Mage-3 peptides presented by HLA class II molecules
WO2002095051A3 (en) Mage-a3 peptides presented by hla class ii molecules
ATE427354T1 (de) Mage-a3 polypeptide die durch hla-klasse ii molekule prasentiert werden
EP1295944A3 (en) GDP dissociation stimulating protein, brain-specific nucleosome assembly protein, skeletal muscle specific ubiquitin-conjugating enzyme, cell proliferation protein, phosphatidylinositolkinase, nel related proteins
WO1999053061A3 (en) Tumor associated nucleic acids and uses therefor
MXPA02002384A (es) Polipeptidos similares al factor de crecimiento de fibroblastos.
MX9705039A (es) Genes y proteinas de muerte celular programada.
EP1005540A4 (en) IKK-BETA PROTEINS, NUCLEIC ACIDS AND METHODS
EP0788307A4 (en) MODULATION BY OLIGONUCLEOTIDES OF THE PROTEIN ASSOCIATED WITH MULTIPLE ANTI-CANCER RESISTANCE
ATE295889T1 (de) Gentranskription und ionisierende strahlung: methoden und zusammensetzungen
TR200700740T2 (tr) Nogo genlerinin nükleotid ve protein dizileri ve bunlar bazında yöntemler
DE69924826D1 (de) Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
DE69839444D1 (de) Smad 6 und dessen anwendungen
EP0804609A4 (en) NEW GENES OF RESPONSE p53
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
WO1998059040A3 (de) Humane katalytische telomerase-untereinheit und deren diagnostische und therapeutische verwendung
NZ302821A (en) isolated truncated nucleic acid molecules which code for GAGE tumour rejection antigen precursors
ATE310085T1 (de) Cyclin-e2 proteine und dafür kodierende gene
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
ATE496129T1 (de) Von hla-klasse-ii-molekülen präsentierte ssx-2- peptide
PT970206E (pt) Ácidos nucleicos lage-1 associados a tumores
WO2001072826A3 (en) Oncogenic osteomalacia-related gene 1
DE69733948D1 (de) In vivo herstellung von replicativen molekülen
WO2004078918A3 (en) Materials and methods relating to therapy and diagnosis using targeting of cells that express dcal-hy polypeptides
WO2004019283A3 (en) Methods for regulating transcription by targeting quadruplex dna